<DOC>
	<DOCNO>NCT02707861</DOCNO>
	<brief_summary>Ibalizumab monoclonal antibody work block HIV entry immune system cell ( CD4+ T-cells ) virus typically infect . Ibalizumab intend use combination anti-HIV drug people multi-drug resistant HIV limit treatment option . This study collect information safety tolerability intravenously administer ( IV ) ibalizumab combine optimize background regimen treat multi-drug resistant HIV-1 infection , provide continue access ibalizumab patient complete prior ibalizumab clinical trial .</brief_summary>
	<brief_title>Ibalizumab Plus Optimized Background Regimen Treatment-Experienced Patients With Multi-Drug Resistant HIV-1</brief_title>
	<detailed_description>Participants enroll one two study cohort . Cohort 1 provide continue administration IV ibalizumab patient complete prior ibalizumab clinical trial ( TaiMed-sponsored Investigator-Sponsored ) . Patients continue receive IV infusion ibalizumab dosage assign previous study - either 800 mg every two week , 2000 mg every four week . Cohort 2 provide IV ibalizumab , 800 mg every two week , qualify patient multi-drug resistant HIV-1 limit treatment option never previously receive ibalizumab . Participants may continue study 48 week , ibalizumab becomes commercially available , whichever occur first .</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>( Cohort 1 ) Currently receive ibalizumab via TaiMedsponsored investigatorSponsored protocol Are capable understand voluntarily sign inform consent document ( Cohort 2 ) 18 year age old Are capable understand voluntarily sign inform consent document Have document HIV1 infection official , sign , write history ( e.g. , laboratory report ) , otherwise HIVantibody test performed Are able willing comply protocol requirement procedure Have viral load &gt; 1,000 copies/mL document resistance least one antiretroviral medication three class antiretroviral medication measure previous viral resistance testing ( resistance test provide study qualification purpose ) Have history least 6 month antiretroviral treatment Are receive fail antiretroviral regimen OR fail therapy Have viral sensitivity/susceptibility least one antiretroviral agent , ibalizumab , determine previous resistance test perform within 6 month screen willing able treat least one agent patient 's viral isolate fully sensitive/susceptible accord resistance test use screen component OBR If sexually active , willing use effective method contraception study 30 day last administration study drug ( Cohort 1 ) There Exclusion Criteria patient meet Inclusion Criteria Cohort 1 ( Cohort 2 ) Eligible participation TaiMedsponsored clinical trial ibalizumab Any significant disease ( HIV1 infection ) clinically significant finding , include psychiatric behavioral problem , determine screening , medical history and/or physical examination , investigator 's opinion , would preclude patient participate study Any significant acute illness within 1 week first administration investigational medication study Any active infection secondary HIV require acute therapy ; however , patient require maintenance therapy ( i.e. , secondary prophylaxis opportunistic infection ) eligible study . Any immunomodulating therapy ( include interferon ) , systemic steroid , systemic chemotherapy within 4 week Day 0 Any prior exposure ibalizumab ( formerly TNX355 Hu5A8 ) Any vaccination within 7 day Day 0 Any female patient either pregnant , intend become pregnant , currently breastfeed Any current alcohol illicit drug use , investigator 's opinion , interfere patient 's ability comply study schedule protocol evaluation Any previous clinically significant allergy hypersensitivity excipient ibalizumab formulation Any radiation therapy 28 day first administration investigational medication study Any clinically significant Grade 3 4 laboratory abnormality accord Division AIDS ( DAIDS ) grade scale , except follow asymptomatic Grade 3 event : triglyceride elevation total cholesterol elevation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HIV</keyword>
	<keyword>Resistant</keyword>
	<keyword>Salvage</keyword>
	<keyword>ibalizumab</keyword>
	<keyword>antibody</keyword>
	<keyword>AIDS</keyword>
</DOC>